VitalCare Diabetes Treatment Centers, Inc. (VitalCare) announced it will offer licenses selectively for Diabetes Treatment Centers, moving their patented and FDA approved Intracellular Activation Therapy (iCAT) to market. A license will permit qualified professionals to administer iCAT, which uses a micro-pulse insulin delivery pump in conjunction with proprietary software.

As part of the agreement, the company also offers treatment center setup, staff training and complete ongoing business support.

Medical groups and HMOs may also apply for licenses.

"This is a unique opportunity for all those in the medical field who want to make a difference in the lives of patients with Type 1 and Type 2 diabetes," said Jimmy McDougald, CEO of VitalCare.

VitalCare specializes in comprehensive business services to the diabetes health sector. The corporation includes, with its licensing announcement, a Safe Harbor disclaimer statement regarding potential risks. For more information, see www.vitalcaretechnology.com.

More Voices